PCOS and Depression: Common Links and Potential Targets.
Depression
Inflammation
Insulin resistance (IR)
Insulin-like growth factor 1 (IGF-1)
Obesity
Polycystic ovarian syndrome (PCOS)
Journal
Reproductive sciences (Thousand Oaks, Calif.)
ISSN: 1933-7205
Titre abrégé: Reprod Sci
Pays: United States
ID NLM: 101291249
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
received:
18
03
2021
accepted:
04
10
2021
pubmed:
14
10
2021
medline:
15
11
2022
entrez:
13
10
2021
Statut:
ppublish
Résumé
PCOS or polycystic ovary syndrome is a common endocrine disorder that occurs during the reproductive age in females. It manifests in the form of a wide range of symptoms including (but not limited to) hirsutism, amenorrhea, oligomenorrhea, obesity, acne vulgaris, infertility, alopecia, and insulin resistance. The incidence of depression in PCOS population is increasing as compared to the general population. Increased depression in PCOS significantly alters the quality of life (QOL) of affected females. Also, self-esteem is found to be low in both depression and PCOS. The loss in self-esteem in such patients can be largely attributed to the associated factors including (but not limited to) obesity, acne, androgenic alopecia, and hirsutism. The reason behind the occurrence of depression in PCOS remains elusive to date. Literature suggests that there is an overlap of clinical symptoms between depression and PCOS. As the symptoms overlap, there is a possibility of common associations between depression, PCOS, and PCOS-associated abnormalities including insulin resistance (IR), obesity, CVD, and androgen excess. Studies demonstrate that depression is an inflammatory disorder marked with increased levels of inflammatory markers. On the other hand, PCOS is also regarded as a pro-inflammatory state that is characterized by increased levels of pro-inflammatory markers. Thus, there is a possibility of an inflammatory relationship existing between depression and PCOS. It is also possible that the inflammatory markers in PCOS can cross the blood-brain barrier (BBB) leading to the development of depression. Through the present review, we have attempted to shed light on common associations/shared links between depression and PCOS with respect to the levels of cortisol, androgen, vitamin D, neurotransmitters, monoaminoxidase (MAO), and insulin-like growth factor-1 (IGF-1). Tracking down common associations between depression and PCOS will help find potential drug therapies and improve the QOL of females with depression in PCOS.
Identifiants
pubmed: 34642910
doi: 10.1007/s43032-021-00765-2
pii: 10.1007/s43032-021-00765-2
doi:
Substances chimiques
Androgens
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
3106-3123Informations de copyright
© 2021. Society for Reproductive Investigation.
Références
Zangeneh FZ, Jafarabadi M, Naghizadeh MM, et al. Psychological distress in women with polycystic ovary syndrome from imam khomeini hospital, tehran. J Reprod Infertil. 2012;13:111–5.
pubmed: 23926533
pmcid: 3719335
Chaudhari AP, Mazumdar K, Mehta PD. Anxiety, depression, and quality of life in women with polycystic ovarian syndrome. Indian J Psychol Med. 2018;40:239–46. https://doi.org/10.4103/IJPSYM.IJPSYM_561_17 .
doi: 10.4103/IJPSYM.IJPSYM_561_17
pubmed: 29875531
pmcid: 5968645
Benson S, Hahn S, Tan S, et al. Maladaptive coping with illness in women with polycystic ovary syndrome. J Obstet Gynecol Neonatal Nurs. 2010;39:37–45. https://doi.org/10.1111/j.1552-6909.2009.01086.x .
doi: 10.1111/j.1552-6909.2009.01086.x
pubmed: 20409101
Cooney LG, Lee I, Sammel MD, Dokras A. High prevalence of moderate and severe depressive and anxiety symptoms in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod. 2017;32:1075–91. https://doi.org/10.1093/humrep/dex044 .
doi: 10.1093/humrep/dex044
pubmed: 28333286
Dokras A, Clifton S, Futterweit W, Wild R. Increased prevalence of anxiety symptoms in women with polycystic ovary syndrome: systematic review and meta-analysis. Fertil Steril. 2012;97:225-230.e2. https://doi.org/10.1016/j.fertnstert.2011.10.022 .
doi: 10.1016/j.fertnstert.2011.10.022
pubmed: 22127370
Himelein MJ, Thatcher SS. Polycystic ovary syndrome and mental health: a review. Obstet Gynecol Surv. 2006;61:723–32. https://doi.org/10.1097/01.ogx.0000243772.33357.84 .
doi: 10.1097/01.ogx.0000243772.33357.84
pubmed: 17044949
Janssen O, Hahn S, Tan S, et al. Mood and sexual function in polycystic ovary syndrome. Semin Reprod Med. 2008;26:045–52. https://doi.org/10.1055/s-2007-992924 .
doi: 10.1055/s-2007-992924
Jones GL, Hall JM, Balen AH, Ledger WL. Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. Hum Reprod Update. 2007;14:15–25. https://doi.org/10.1093/humupd/dmm030 .
doi: 10.1093/humupd/dmm030
pubmed: 17905857
Eggers S, Kirchengast S. The polycystic ovary syndrome–a medical condition but also an important psychosocial problem. Coll Antropol. 2001;25:673–85.
pubmed: 11811299
Sadeeqa S, Mustafa T, Latif S. Polycystic ovarian syndrome–related depression in adolescent girls: a review. J Pharm Bioall Sci. 2018;10:55. https://doi.org/10.4103/JPBS.JPBS_1_18 .
doi: 10.4103/JPBS.JPBS_1_18
Månsson M, Holte J, Landin-Wilhelmsen K, et al. Women with polycystic ovary syndrome are often depressed or anxious—a case control study. Psychoneuroendocrinology. 2008;33:1132–8. https://doi.org/10.1016/j.psyneuen.2008.06.003 .
doi: 10.1016/j.psyneuen.2008.06.003
pubmed: 18672334
Fauser BCJM, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28-38.e25. https://doi.org/10.1016/j.fertnstert.2011.09.024 .
doi: 10.1016/j.fertnstert.2011.09.024
pubmed: 22153789
Malik S, Jain K, Talwar P, et al. Management of polycystic ovary syndrome in India. Fertil Sci Res. 2014;1:23.
Firmino Murgel AC, Santos Simões R, Maciel GAR, et al. Sexual dysfunction in women with polycystic ovary syndrome: systematic review and meta-analysis. J Sex Med. 2019;16:542–50. https://doi.org/10.1016/j.jsxm.2019.01.313 .
doi: 10.1016/j.jsxm.2019.01.313
pubmed: 30833151
Norman RJ, Dewailly D, Legro RS, Hickey TE. Polycystic ovary syndrome. Lancet. 2007;370:685–97. https://doi.org/10.1016/S0140-6736(07)61345-2 .
doi: 10.1016/S0140-6736(07)61345-2
pubmed: 17720020
Legro RS, Driscoll D, Strauss JF, et al. Evidence for a genetic basis for hyperandrogenemia in polycystic ovary syndrome. Proc Natl Acad Sci. 1998;95:14956–60. https://doi.org/10.1073/pnas.95.25.14956 .
doi: 10.1073/pnas.95.25.14956
pubmed: 9843997
pmcid: 24557
Nelson VL, Legro RS, Strauss JF, McAllister JM. Augmented androgen production is a stable steroidogenic phenotype of propagated theca cells from polycystic ovaries. Mol Endocrinol. 1999;13:946–57. https://doi.org/10.1210/mend.13.6.0311 .
doi: 10.1210/mend.13.6.0311
pubmed: 10379893
Chaudhari N, Dawalbhakta M, Nampoothiri L. GnRH dysregulation in polycystic ovarian syndrome (PCOS) is a manifestation of an altered neurotransmitter profile. Reprod Biol Endocrinol. 2018;16:37. https://doi.org/10.1186/s12958-018-0354-x .
doi: 10.1186/s12958-018-0354-x
pubmed: 29642911
pmcid: 5896071
Witchel SF, Oberfield SE, Peña AS. Polycystic ovary syndrome: pathophysiology, presentation, and treatment with emphasis on adolescent girls. J Endocr Soc. 2019;3:1545–73. https://doi.org/10.1210/js.2019-00078 .
doi: 10.1210/js.2019-00078
pubmed: 31384717
pmcid: 6676075
Ehrmann DA. Polycystic Ovary Syndrome. N Engl J Med. 2005;352:1223–36. https://doi.org/10.1056/NEJMra041536 .
doi: 10.1056/NEJMra041536
pubmed: 15788499
Tsilchorozidou T, Overton C, Conway GS. The pathophysiology of polycystic ovary syndrome. Clin Endocrinol. 2004;60:1–17. https://doi.org/10.1046/j.1365-2265.2003.01842.x .
doi: 10.1046/j.1365-2265.2003.01842.x
Jonard S. The follicular excess in polycystic ovaries, due to intra-ovarian hyperandrogenism, may be the main culprit for the follicular arrest. Hum Reprod Update. 2004;10:107–17. https://doi.org/10.1093/humupd/dmh010 .
doi: 10.1093/humupd/dmh010
pubmed: 15073141
Rang HP, Ritter JM, Flower RJ, Henderson G. Rang & Dale’s Pharmacology E-Book: with STUDENT CONSULT Online Access. 2014.
Malhi GS, Mann JJ. Depression. Lancet. 2018;392:2299–312. https://doi.org/10.1016/S0140-6736(18)31948-2 .
doi: 10.1016/S0140-6736(18)31948-2
pubmed: 30396512
Murthy RS. National Mental Health Survey of India 2015–2016. Indian J Psychiatry. 2017;59:21–6. https://doi.org/10.4103/psychiatry.IndianJPsychiatry_102_17 .
doi: 10.4103/psychiatry.IndianJPsychiatry_102_17
pubmed: 28529357
pmcid: 5419008
World Health Organization. Depression and other common mental disorders: global health estimates. World Health Organization; 2017.
Sadeeqa S, Mustafa T, Latif S. Polycystic ovarian syndrome-related depression in adolescent girls: a review. J Pharm Bioallied Sci. 2018;10:55–9. https://doi.org/10.4103/JPBS.JPBS_1_18 .
doi: 10.4103/JPBS.JPBS_1_18
pubmed: 29962792
pmcid: 5998697
Ibáñez L, Oberfield SE, Witchel S, et al. An international consortium update: pathophysiology, diagnosis, and treatment of polycystic ovarian syndrome in adolescence. Horm Res Paediatr. 2017;88:371–95. https://doi.org/10.1159/000479371 .
doi: 10.1159/000479371
pubmed: 29156452
Diamanti-Kandarakis E. Polycystic ovarian syndrome: pathophysiology, molecular aspects and clinical implications. Expert Rev Mol Med. 2008;10: e3. https://doi.org/10.1017/S1462399408000598 .
doi: 10.1017/S1462399408000598
pubmed: 18230193
Diamanti-Kandarakis E. PCOS in adolescents. Best Pract Res Clin Obstet Gynaecol. 2010;24:173–83. https://doi.org/10.1016/j.bpobgyn.2009.09.005 .
doi: 10.1016/j.bpobgyn.2009.09.005
pubmed: 19932060
Wood JR, Ho CKM, Nelson-Degrave VL, et al. The molecular signature of polycystic ovary syndrome (PCOS) theca cells defined by gene expression profiling. J Reprod Immunol. 2004;63:51–60. https://doi.org/10.1016/j.jri.2004.01.010 .
doi: 10.1016/j.jri.2004.01.010
pubmed: 15284005
Fekadu N, Shibeshi W, Engidawork E. Major depressive disorder: pathophysiology and clinical management. J Depress Anxiety. 2017;06. https://doi.org/10.4172/2167-1044.1000255 .
Saveanu RV, Nemeroff CB. Etiology of depression: genetic and environmental factors. Psychiatr Clin N Am. 2012;35:51–71. https://doi.org/10.1016/j.psc.2011.12.001 .
doi: 10.1016/j.psc.2011.12.001
McCauley J, Kern DE, Kolodner K, et al. Clinical characteristics of women with a history of childhood abuse: unhealed wounds. JAMA. 1997;277:1362–8.
doi: 10.1001/jama.1997.03540410040028
pubmed: 9134941
Mullen PE, Martin JL, Anderson JC, et al. The long-term impact of the physical, emotional, and sexual abuse of children: a community study. Child Abuse Negl. 1996;20:7–21. https://doi.org/10.1016/0145-2134(95)00112-3 .
doi: 10.1016/0145-2134(95)00112-3
pubmed: 8640429
Young EA, Abelson JL, Curtis GC, Nesse RM. Childhood adversity and vulnerability to mood and anxiety disorders. Depress Anxiety. 1997;5:66–72.
doi: 10.1002/(SICI)1520-6394(1997)5:2<66::AID-DA2>3.0.CO;2-3
pubmed: 9262936
Zlotnick C, Ryan CE, Miller IW, Keitner GI. Childhood abuse and recovery from major depression. Child Abuse Negl. 1995;19:1513–6. https://doi.org/10.1016/0145-2134(95)00098-6 .
doi: 10.1016/0145-2134(95)00098-6
pubmed: 8777700
Heim C, Newport DJ, Mletzko T, et al. The link between childhood trauma and depression: insights from HPA axis studies in humans. Psychoneuroendocrinology. 2008;33:693–710. https://doi.org/10.1016/j.psyneuen.2008.03.008 .
doi: 10.1016/j.psyneuen.2008.03.008
pubmed: 18602762
Kaplan MJ, Klinetob NA. Childhood emotional trauma and chronic posttraumatic stress disorder in adult outpatients with treatment-resistant depression. J Nerv Ment Dis. 2000;188:596–601. https://doi.org/10.1097/00005053-200009000-00006 .
doi: 10.1097/00005053-200009000-00006
pubmed: 11009333
Lara ME, Klein DN, Kasch KL. Psychosocial predictors of the short-term course and outcome of major depression: a longitudinal study of a nonclinical sample with recent-onset episodes. J Abnorm Psychol. 2000;109:644–50. https://doi.org/10.1037/0021-843X.109.4.644 .
doi: 10.1037/0021-843X.109.4.644
pubmed: 11195988
Hasler G. Pathophysiology of depression: do we have any solid evidence of interest to clinicians? World Psychiatry. 2010;9:155–61. https://doi.org/10.1002/j.2051-5545.2010.tb00298.x .
doi: 10.1002/j.2051-5545.2010.tb00298.x
pubmed: 20975857
pmcid: 2950973
Cowen P. Serotonin and depression: pathophysiological mechanism or marketing myth? Trends Pharmacol Sci. 2008;29:433–6. https://doi.org/10.1016/j.tips.2008.05.004 .
doi: 10.1016/j.tips.2008.05.004
pubmed: 18585794
Saldanha D, Kumar N, Ryali V, et al. Serum serotonin abnormality in depression. Med J Armed Forces India. 2009;65:108–12. https://doi.org/10.1016/S0377-1237(09)80120-2 .
doi: 10.1016/S0377-1237(09)80120-2
pubmed: 27408213
pmcid: 4921409
Kanchanatawan B, Sirivichayakul S, Thika S, et al. Physio-somatic symptoms in schizophrenia: association with depression, anxiety, neurocognitive deficits and the tryptophan catabolite pathway. Metab Brain Dis. 2017;32:1003–16. https://doi.org/10.1007/s11011-017-9982-7 .
doi: 10.1007/s11011-017-9982-7
pubmed: 28258445
Gałecki P, Talarowska M. Inflammatory theory of depression. Psychiatr Pol. 2018;52:437–447. https://doi.org/10.12740/PP/76863 .
Anderson G. Editorial (Thematic Issue: The kynurenine and melatonergic pathways in psychiatric and CNS disorders). CPD. 2016;22:947–8. https://doi.org/10.2174/1381612822999160104143932 .
doi: 10.2174/1381612822999160104143932
Raghavendra V, Kulkarni SK. Melatonin reversal of DOI-induced hypophagia in rats; possible mechanism by suppressing 5-HT2A receptor-mediated activation of HPA axis. Brain Res. 2000;860:112–8. https://doi.org/10.1016/S0006-8993(00)02031-X .
doi: 10.1016/S0006-8993(00)02031-X
pubmed: 10727629
Terzieva DD, Orbetzova MM, Mitkov MD, Mateva NG. Serum melatonin in women with polycystic ovary syndrome. Folia Med. 2013;55:10–5. https://doi.org/10.2478/folmed-2013-0012 .
doi: 10.2478/folmed-2013-0012
De Berardis D, Orsolini L, Serroni N, et al. The role of melatonin in mood disorders. CPT. 2015;65. https://doi.org/10.2147/CPT.S41761 .
Groves JO. Is it time to reassess the BDNF hypothesis of depression? Mol Psychiatry. 2007;12:1079–88. https://doi.org/10.1038/sj.mp.4002075 .
doi: 10.1038/sj.mp.4002075
pubmed: 17700574
Ranabir S, Reetu K. Stress and hormones. Indian J Endocrinol Metab. 2011;15:18–22. https://doi.org/10.4103/2230-8210.77573 .
doi: 10.4103/2230-8210.77573
pubmed: 21584161
pmcid: 3079864
de Souza DN, de Almeida Corrêa LM, Assunção LR, et al. Relation between depression and hormonal dysregulation. OJD. 2017;06:69–78. https://doi.org/10.4236/ojd.2017.63005 .
doi: 10.4236/ojd.2017.63005
Basu BR, Chowdhury O, Saha SK. Possible link between stress-related factors and altered body composition in women with polycystic ovarian syndrome. J Hum Reprod Sci. 2018;11:10–8. https://doi.org/10.4103/jhrs.JHRS_78_17 .
doi: 10.4103/jhrs.JHRS_78_17
pubmed: 29681710
pmcid: 5892097
Hollinrake E, Abreu A, Maifeld M, et al. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril. 2007;87:1369–76. https://doi.org/10.1016/j.fertnstert.2006.11.039 .
doi: 10.1016/j.fertnstert.2006.11.039
pubmed: 17397839
Rasgon NL, Carter MS, Elman S, et al. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord. 2002;2:97–102.
doi: 10.2174/1568005310202010097
pubmed: 12477299
Nathan RS, Sachar EJ, Asnis GM, et al. Relative insulin insensitivity and cortisol secretion in depressed patients. Psychiatry Res. 1981;4:291–300. https://doi.org/10.1016/0165-1781(81)90031-7 .
doi: 10.1016/0165-1781(81)90031-7
pubmed: 7022525
Tashiro A, Hongo M, Ota R, et al. Hyper-insulin response in a patient with depression: changes in insulin resistance during recovery from depression. Diabetes Care. 1997;20:1924–5. https://doi.org/10.2337/diacare.20.12.1924 .
doi: 10.2337/diacare.20.12.1924
pubmed: 9405924
Winokur A, Maislin G, Phillips JL, Amsterdam JD. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am J Psychiatry. 1988;145:325–30. https://doi.org/10.1176/ajp.145.3.325 .
doi: 10.1176/ajp.145.3.325
pubmed: 2894176
Okamura F, Tashiro A, Utumi A, et al. Insulin resistance in patients with depression and its changes during the clinical course of depression: minimal model analysis. Metabolism. 2000;49:1255–60. https://doi.org/10.1053/meta.2000.9515 .
doi: 10.1053/meta.2000.9515
pubmed: 11079812
Sam S. Obesity and polycystic ovary syndrome. Obes Manag. 2007;3:69–73. https://doi.org/10.1089/obe.2007.0019 .
doi: 10.1089/obe.2007.0019
pubmed: 20436797
pmcid: 2861983
Dixon JB, Dixon ME, O’Brien PE. Depression in association with severe obesity: changes with weight loss. Arch Intern Med. 2003;163:2058. https://doi.org/10.1001/archinte.163.17.2058 .
doi: 10.1001/archinte.163.17.2058
pubmed: 14504119
Lee SH, Paz-Filho G, Mastronardi C, et al. Is increased antidepressant exposure a contributory factor to the obesity pandemic? Transl Psychiatry. 2016;6:e759–e759. https://doi.org/10.1038/tp.2016.25 .
doi: 10.1038/tp.2016.25
pubmed: 26978741
pmcid: 4872449
Ranabir S, Reetu K. Stress and hormones. Indian J Endocr Metab. 2011;15:18. https://doi.org/10.4103/2230-8210.77573 .
doi: 10.4103/2230-8210.77573
Björntorp P. Do stress reactions cause abdominal obesity and comorbidities? Obes Rev. 2001;2:73–86. https://doi.org/10.1046/j.1467-789x.2001.00027.x .
doi: 10.1046/j.1467-789x.2001.00027.x
pubmed: 12119665
Adali E, Yildizhan R, Kurdoglu M, et al. The relationship between clinico-biochemical characteristics and psychiatric distress in young women with polycystic ovary syndrome. J Int Med Res. 2008;36:1188–96. https://doi.org/10.1177/147323000803600604 .
doi: 10.1177/147323000803600604
pubmed: 19094426
Elsenbruch S, Benson S, Hahn S, et al. Determinants of emotional distress in women with polycystic ovary syndrome. Hum Reprod. 2006;21:1092–9. https://doi.org/10.1093/humrep/dei409 .
doi: 10.1093/humrep/dei409
pubmed: 16459352
Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord. 2003;74:299–304. https://doi.org/10.1016/s0165-0327(02)00117-9 .
doi: 10.1016/s0165-0327(02)00117-9
pubmed: 12738050
Acién P, Quereda F, Matallı́n P, et al. Insulin, androgens, and obesity in women with and without polycystic ovary syndrome: a heterogeneous group of disorders. Fertil Steril. 1999;72:32–40. https://doi.org/10.1016/S0015-0282(99)00184-3 .
doi: 10.1016/S0015-0282(99)00184-3
pubmed: 10428145
Annagür BB, Tazegül A, Uguz F, et al. Biological correlates of major depression and generalized anxiety disorder in women with polycystic ovary syndrome. J Psychosom Res. 2013;74:244–7. https://doi.org/10.1016/j.jpsychores.2013.01.002 .
doi: 10.1016/j.jpsychores.2013.01.002
pubmed: 23438716
Weber B, Lewicka S, Deuschle M, et al. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology. 2000;25:765–71. https://doi.org/10.1016/S0306-4530(00)00023-8 .
doi: 10.1016/S0306-4530(00)00023-8
pubmed: 10996472
Weiner CL. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med. 2004;66:356–62. https://doi.org/10.1097/01.psy.0000127871.46309.fe .
doi: 10.1097/01.psy.0000127871.46309.fe
pubmed: 15184695
Meyer JH, Ginovart N, Boovariwala A, et al. Elevated monoamine oxidase a levels in the brain: an explanation for the monoamine imbalance of major depression. Arch Gen Psychiatry. 2006;63:1209–16. https://doi.org/10.1001/archpsyc.63.11.1209 .
doi: 10.1001/archpsyc.63.11.1209
pubmed: 17088501
Moriguchi S, Wilson AA, Miler L, et al. Monoamine oxidase B total distribution volume in the prefrontal cortex of major depressive disorder: an [
Shi X, Zhang L, Fu S, Li N. Co-involvement of psychological and neurological abnormalities in infertility with polycystic ovarian syndrome. Arch Gynecol Obstet. 2011;284:773–8. https://doi.org/10.1007/s00404-011-1947-1 .
doi: 10.1007/s00404-011-1947-1
pubmed: 21688169
Thomson RL, Spedding S, Buckley JD. Vitamin D in the aetiology and management of polycystic ovary syndrome. Clin Endocrinol. 2012;77:343–50. https://doi.org/10.1111/j.1365-2265.2012.04434.x .
doi: 10.1111/j.1365-2265.2012.04434.x
Moran LJ, Teede HJ, Vincent AJ. Vitamin D is independently associated with depression in overweight women with and without PCOS. Gynecol Endocrinol. 2015;31:179–82. https://doi.org/10.3109/09513590.2014.975682 .
doi: 10.3109/09513590.2014.975682
pubmed: 25366261
Krul-Poel YHM, Koenders PP, Steegers-Theunissen RP, et al. Vitamin D and metabolic disturbances in polycystic ovary syndrome (PCOS): a cross-sectional study. PLoS ONE. 2018;13: e0204748. https://doi.org/10.1371/journal.pone.0204748 .
doi: 10.1371/journal.pone.0204748
pubmed: 30513089
pmcid: 6279035
Li HWR, Brereton RE, Anderson RA, et al. Vitamin D deficiency is common and associated with metabolic risk factors in patients with polycystic ovary syndrome. Metabolism. 2011;60:1475–81. https://doi.org/10.1016/j.metabol.2011.03.002 .
doi: 10.1016/j.metabol.2011.03.002
pubmed: 21550088
Hahn S, Haselhorst U, Tan S, et al. Low serum 25-hydroxyvitamin D concentrations are associated with insulin resistance and obesity in women with polycystic ovary syndrome. Exp Clin Endocrinol Diabetes. 2006;114:577–83. https://doi.org/10.1055/s-2006-948308 .
doi: 10.1055/s-2006-948308
pubmed: 17177140
Pal L, Shu J, Zeitlian G, Hickmon C. Vitamin D insufficiency in reproductive years may be contributory to ovulatory infertility and PCOS. Fertil Steril. 2008;90:S14. https://doi.org/10.1016/j.fertnstert.2008.07.382 .
doi: 10.1016/j.fertnstert.2008.07.382
Wehr E, Pilz S, Schweighofer N, et al. Association of hypovitaminosis D with metabolic disturbances in polycystic ovary syndrome. Eur J Endocrinol. 2009;161:575–82. https://doi.org/10.1530/EJE-09-0432 .
doi: 10.1530/EJE-09-0432
pubmed: 19628650
Yildizhan R, Kurdoglu M, Adali E, et al. Serum 25-hydroxyvitamin D concentrations in obese and non-obese women with polycystic ovary syndrome. Arch Gynecol Obstet. 2009;280:559–63. https://doi.org/10.1007/s00404-009-0958-7 .
doi: 10.1007/s00404-009-0958-7
pubmed: 19214546
Shi H, Wang B, Xu X. Antidepressant effect of vitamin D: a literature review. Neuropsychiatry. 2018;07. https://doi.org/10.4172/Neuropsychiatry.1000219 .
Antai-Otong D. Vitamin D: an anti-inflammatory treatment option for depression? Issues Ment Health Nurs. 2014;35:227–34. https://doi.org/10.3109/01612840.2013.875086 .
doi: 10.3109/01612840.2013.875086
pubmed: 24597590
Blundell TL, Humbel RE. Hormone families: pancreatic hormones and homologous growth factors. Nature. 1980;287:781–7. https://doi.org/10.1038/287781a0 .
doi: 10.1038/287781a0
pubmed: 6107857
Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem. 1978;253:2769–76.
doi: 10.1016/S0021-9258(17)40889-1
pubmed: 632300
Laron Z. Insulin-like growth factor 1 (IGF-1): a growth hormone. MP Mol Pathol. 2001;54:311–6. https://doi.org/10.1136/mp.54.5.311 .
doi: 10.1136/mp.54.5.311
pubmed: 11577173
D’Ercole AJ, Applewhite GT, Underwood LE. Evidence that somatomedin is synthesized by multiple tissues in the fetus. Dev Biol. 1980;75:315–28. https://doi.org/10.1016/0012-1606(80)90166-9 .
doi: 10.1016/0012-1606(80)90166-9
pubmed: 7372001
Baserga R. The IGF-I receptor in cancer research. Exp Cell Res. 1999;253:1–6. https://doi.org/10.1006/excr.1999.4667 .
doi: 10.1006/excr.1999.4667
pubmed: 10579905
Nilsson A, Isgaard J, Lindahl A, et al. Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science. 1986;233:571–4. https://doi.org/10.1126/science.3523759 .
doi: 10.1126/science.3523759
pubmed: 3523759
Kelley KM, Oh Y, Gargosky SE, et al. Insulin-like growth factor-binding proteins (IGFBPs) and their regulatory dynamics. Int J Biochem Cell Biol. 1996;28:619–37. https://doi.org/10.1016/1357-2725(96)00005-2 .
doi: 10.1016/1357-2725(96)00005-2
pubmed: 8673727
Hwa V, Oh Y, Rosenfeld RG. The insulin-like growth factor-binding protein (IGFBP)superfamily*. Endocr Rev. 1999;20:761–87. https://doi.org/10.1210/edrv.20.6.0382 .
doi: 10.1210/edrv.20.6.0382
pubmed: 10605625
Baxter RC. Insulin-like growth factor binding proteins in the human circulation: a review. Horm Res. 1994;42:140–4. https://doi.org/10.1159/000184186 .
doi: 10.1159/000184186
pubmed: 7532612
Lee PDK, Giudice LC, Conover CA, Powell DR. Insulin-like growth factor binding protein-1: recent findings and new directions. Exp Biol Med. 1997;216:319–57. https://doi.org/10.3181/00379727-216-44182 .
doi: 10.3181/00379727-216-44182
Laron Z, Suikkari A-M, Klinger B, et al. Growth hormone and insulin-like growth factor regulate insulin-like growth factor-binding protein-1 in Laron type dwarfism, growth hormone deficiency and constitutional short stature. Acta Endocrinol. 1992;127:351–8. https://doi.org/10.1530/acta.0.1270351 .
doi: 10.1530/acta.0.1270351
Bredt DS, Furey ML, Chen G, et al. Translating depression biomarkers for improved targeted therapies. Neurosci Biobehav Rev. 2015;59:1–15. https://doi.org/10.1016/j.neubiorev.2015.09.013 .
doi: 10.1016/j.neubiorev.2015.09.013
pubmed: 26432926
Pittenger C, Duman RS. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology. 2008;33:88–109. https://doi.org/10.1038/sj.npp.1301574 .
doi: 10.1038/sj.npp.1301574
pubmed: 17851537
Duman RS. Role of neurotrophic factors in the etiology and treatment of mood disorders. NMM. 2004;5:011–26. https://doi.org/10.1385/NMM:5:1:011 .
doi: 10.1385/NMM:5:1:011
Szczęsny E, Ślusarczyk J, Głombik K, et al. Possible contribution of IGF-1 to depressive disorder. Pharmacol Rep. 2013;65:1622–31. https://doi.org/10.1016/S1734-1140(13)71523-8 .
doi: 10.1016/S1734-1140(13)71523-8
pubmed: 24553010
Russo VC, Gluckman PD, Feldman EL, Werther GA. The insulin-like growth factor system and its pleiotropic functions in brain. Endocr Rev. 2005;26:916–43. https://doi.org/10.1210/er.2004-0024 .
doi: 10.1210/er.2004-0024
pubmed: 16131630
Lobo RA, Carmina E. The importance of diagnosing the polycystic ovary syndrome. Ann Intern Med. 2000;132:989. https://doi.org/10.7326/0003-4819-132-12-200006200-00010 .
doi: 10.7326/0003-4819-132-12-200006200-00010
pubmed: 10858183
Elting MW, Korsen TJM, Bezemer PD, Schoemaker J. Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. Hum Reprod. 2001;16:556–60. https://doi.org/10.1093/humrep/16.3.556 .
doi: 10.1093/humrep/16.3.556
pubmed: 11228228
Escobar-Morreale HF, Roldán B, Barrio R, et al. High prevalence of the polycystic ovary syndrome and hirsutism in women with type 1 diabetes mellitus1. J Clin Endocrinol Metab. 2000;85:4182–7. https://doi.org/10.1210/jcem.85.11.6931 .
doi: 10.1210/jcem.85.11.6931
pubmed: 11095451
Kelly CJG, Speirs A, Gould GW, et al. Altered vascular function in young women with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002;87:742–6. https://doi.org/10.1210/jcem.87.2.8199 .
doi: 10.1210/jcem.87.2.8199
pubmed: 11836314
Mather KJ, Kwan F, Corenblum B. Hyperinsulinemia in polycystic ovary syndrome correlates with increased cardiovascular risk independent of obesity. Fertil Steril. 2000;73:150–6. https://doi.org/10.1016/S0015-0282(99)00468-9 .
doi: 10.1016/S0015-0282(99)00468-9
pubmed: 10632431
Dessapt-Baradez C, Reza M, Sivakumar G, et al. Circulating vascular progenitor cells and central arterial stiffness in polycystic ovary syndrome. PLoS ONE. 2011;6: e20317. https://doi.org/10.1371/journal.pone.0020317 .
doi: 10.1371/journal.pone.0020317
pubmed: 21655296
pmcid: 3105021
Desai NA, Patel SS. Increased insulin-like growth factor-1 in relation to cardiovascular function in polycystic ovary syndrome: friend or foe? Gynecol Endocrinol. 2015;31:801–7. https://doi.org/10.3109/09513590.2015.1075497 .
doi: 10.3109/09513590.2015.1075497
pubmed: 26288196
Homburg R, Pariente C, Lunenfeld B, Jacobs HS. The role of insulin-like growth factor-1 (IGF-1) and IGF binding protein-1 (IGFBP-1) in the pathogenesis of polycystic ovary syndrome. Hum Reprod. 1992;7:1379–83. https://doi.org/10.1093/oxfordjournals.humrep.a137577 .
doi: 10.1093/oxfordjournals.humrep.a137577
pubmed: 1283982
Conway GS, Jacobs HS, Holly JMP, Wass JAH. Effects of luteinizing hormone, insulin, insulin-like growth factor-I and insulinlike growth factor small binding protein 1 in the polycystic ovary syndrome. Clin Endocrinol. 2009;33:593–603. https://doi.org/10.1111/j.1365-2265.1990.tb03897.x .
doi: 10.1111/j.1365-2265.1990.tb03897.x
Iwashita M, Mimuro T, Watanabe M, et al. Plasma levels of insulin-like growth factor-I and its binding protein in polycystic ovary syndrome. Horm Res. 1990;33:21–6. https://doi.org/10.1159/000181561 .
doi: 10.1159/000181561
pubmed: 1710201
van Dessel HJHMT, Lee PDK, Faessen G, et al. Elevated serum levels of free insulin-like growth factor I in polycystic ovary syndrome
doi: 10.1210/jcem.84.9.5941
Carmina E, Wong L, Chang L, et al. Endocrine abnormalities in ovulatory women with polycystic ovaries on ultrasound. Hum Reprod. 1997;12:905–9. https://doi.org/10.1093/humrep/12.5.905 .
doi: 10.1093/humrep/12.5.905
pubmed: 9194637
Wang H, Chard T. IGFs and IGF-binding proteins in the regulation of human ovarian and endometrial function. J Endocrinol. 1999;161:1–13. https://doi.org/10.1677/joe.0.1610001 .
doi: 10.1677/joe.0.1610001
pubmed: 10194523
Barbieri RL. Hyperandrogenism, insulin resistance and acanthosis nigricans. 10 years of progress. J Reprod Med. 1994;39:327–36.
pubmed: 8064699
Bergh C, Carlsson B, Olsson J-H, et al. Regulation of androgen production in cultured human thecal cells by insulin-like growth factor I and insulin**Supported by grant no. 5987 from the Swedish Medical Research Council, Swedish Medical Society, The Medical Society of Göteborg, Kabi-Pharmacia Ltd., Nordisk Insulin Foundation, Hjalmar Svenssons Research Foundation, Swedish Society for Medical Research, and the University of Göteborg, Göteborg, Sweden. Fertil Steril. 1993;59:323–31. https://doi.org/10.1016/S0015-0282(16)55675-1 .
doi: 10.1016/S0015-0282(16)55675-1
pubmed: 8425626
Nagamani M, Stuart CA. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis. Am J Obstet Gynecol. 1990;163:1992–7. https://doi.org/10.1016/0002-9378(90)90786-7 .
doi: 10.1016/0002-9378(90)90786-7
pubmed: 2175151
Poretsky L, Chandrasekher YA, Bai C, et al. Insulin receptor mediates inhibitory effect of insulin, but not of insulin-like growth factor (IGF)-I, on IGF binding protein 1 (IGFBP-1) production in human granulosa cells. J Clin Endocrinol Metab. 1996;81:493–6. https://doi.org/10.1210/jcem.81.2.8636256 .
doi: 10.1210/jcem.81.2.8636256
pubmed: 8636256
Deuschle M, Blum WF, Strasburger CJ, et al. Insulin-like growth factor-I (IGF-I) plasma concentrations are increased in depressed patients. Psychoneuroendocrinology. 1997;22:493–503. https://doi.org/10.1016/S0306-4530(97)00046-2 .
doi: 10.1016/S0306-4530(97)00046-2
pubmed: 9373883
Kopczak A, Stalla GK, Uhr M, et al. IGF-I in major depression and antidepressant treatment response. Eur Neuropsychopharmacol. 2015;25:864–72. https://doi.org/10.1016/j.euroneuro.2014.12.013 .
doi: 10.1016/j.euroneuro.2014.12.013
pubmed: 25836355
Sievers C, Auer MK, Klotsche J, et al. IGF-I levels and depressive disorders: results from the Study of Health in Pomerania (SHIP). Eur Neuropsychopharmacol. 2014;24:890–6. https://doi.org/10.1016/j.euroneuro.2014.01.008 .
doi: 10.1016/j.euroneuro.2014.01.008
pubmed: 24507017
Jedel E, Gustafson D, Waern M, et al. Sex steroids, insulin sensitivity and sympathetic nerve activity in relation to affective symptoms in women with polycystic ovary syndrome. Psychoneuroendocrinology. 2011;36:1470–9. https://doi.org/10.1016/j.psyneuen.2011.04.001 .
doi: 10.1016/j.psyneuen.2011.04.001
pubmed: 21549510
Franz B, Buysse DJ, Cherry CR, et al. Insulin-like growth factor 1 and growth hormone binding protein in depression: a preliminary communication. J Psychiatr Res. 1999;33:121–7. https://doi.org/10.1016/S0022-3956(98)00066-1 .
doi: 10.1016/S0022-3956(98)00066-1
pubmed: 10221744
Bot M, Milaneschi Y, Penninx BWJH, Drent ML. Plasma insulin-like growth factor I levels are higher in depressive and anxiety disorders, but lower in antidepressant medication users. Psychoneuroendocrinology. 2016;68:148–55. https://doi.org/10.1016/j.psyneuen.2016.02.028 .
doi: 10.1016/j.psyneuen.2016.02.028
pubmed: 26974499
Ferketich AK, Schwartzbaum JA, Frid DJ, Moeschberger ML. Depression as an antecedent to heart disease among women and men in the NHANES I study. Arch Intern Med. 2000;160:1261. https://doi.org/10.1001/archinte.160.9.1261 .
doi: 10.1001/archinte.160.9.1261
pubmed: 10809028
Katon WJ, Lin EHB, Russo J, et al. Cardiac risk factors in patients with diabetes mellitus and major depression. J Gen Intern Med. 2004;19:1192–9. https://doi.org/10.1111/j.1525-1497.2004.30405.x .
doi: 10.1111/j.1525-1497.2004.30405.x
pubmed: 15610329
pmcid: 1492592
Moran LJ, Misso ML, Wild RA, Norman RJ. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–63. https://doi.org/10.1093/humupd/dmq001 .
doi: 10.1093/humupd/dmq001
pubmed: 20159883
Boquist S, Ruotolo G, Skoglund-Andersson C, et al. Correlation of serum IGF-I and IGFBP-1 and -3 to cardiovascular risk indicators and early carotid atherosclerosis in healthy middle-aged men. Clin Endocrinol. 2008;68:51–8. https://doi.org/10.1111/j.1365-2265.2007.02998.x .
doi: 10.1111/j.1365-2265.2007.02998.x
Jörn Schneider H, Klotsche J, Saller B, et al. Associations of age-dependent IGF-I SDS with cardiovascular diseases and risk conditions: cross-sectional study in 6773 primary care patients. Eur J Endocrinol. 2008;158:153–61. https://doi.org/10.1530/EJE-07-0600 .
doi: 10.1530/EJE-07-0600
Al-Obaidi MK, Hon JKF, Stubbs PJ, et al. Plasma insulin-like growth factor-1 elevated in mild-to-moderate but not severe heart failure. Am Heart J. 2001;142:11A-15A. https://doi.org/10.1067/mhj.2001.118116 .
doi: 10.1067/mhj.2001.118116
Andreassen M, Raymond I, Kistorp C, et al. IGF1 as predictor of all cause mortality and cardiovascular disease in an elderly population. Eur J Endocrinol. 2009;160:25–31. https://doi.org/10.1530/EJE-08-0452 .
doi: 10.1530/EJE-08-0452
pubmed: 18931092
Fischer F, Schulte H, Mohan S, et al. Associations of insulin-like growth factors, insulin-like growth factor binding proteins and acid-labile subunit with coronary heart disease. Clin Endocrinol. 2004;61:595–602. https://doi.org/10.1111/j.1365-2265.2004.02136.x .
doi: 10.1111/j.1365-2265.2004.02136.x
van Bunderen CC, van Nieuwpoort IC, van Schoor NM, et al. The association of serum insulin-like growth factor-I with mortality, cardiovascular disease, and cancer in the elderly: a population-based study. J Clin Endocrinol Metab. 2010;95:4616–24. https://doi.org/10.1210/jc.2010-0940 .
doi: 10.1210/jc.2010-0940
pubmed: 20610588
Spallarossa P, Brunelli C, Minuto F, et al. Insulin-like growth factor-1 and angiographically documented coronary artery disease. Am J Cardiol. 1996;77:200–2. https://doi.org/10.1016/S0002-9149(96)90600-1 .
doi: 10.1016/S0002-9149(96)90600-1
pubmed: 8546095
Juul A, Scheike T, Davidsen M, et al. Low serum insulin-like growth factor I is associated with increased risk of ischemic heart disease: a population-based case-control study. Circulation. 2002;106:939–44. https://doi.org/10.1161/01.CIR.0000027563.44593.CC .
doi: 10.1161/01.CIR.0000027563.44593.CC
pubmed: 12186797
Laughlin GA, Barrett-Connor E, Criqui MH, Kritz-Silverstein D. The prospective association of serum insulin-like growth factor I (IGF-I) and IGF-binding protein-1 levels with all cause and cardiovascular disease mortality in older adults: the Rancho Bernardo Study. J Clin Endocrinol Metab. 2004;89:114–20. https://doi.org/10.1210/jc.2003-030967 .
doi: 10.1210/jc.2003-030967
pubmed: 14715837
Cicoira M, Kalra PR, Anker SD. Growth hormone resistance in chronic heart failure and its therapeutic implications. J Cardiac Fail. 2003;9:219–26. https://doi.org/10.1054/jcaf.2003.23 .
doi: 10.1054/jcaf.2003.23
Jankowska EA, Biel B, Majda J, et al. Anabolic deficiency in men with chronic heart failure: prevalence and detrimental impact on survival. Circulation. 2006;114:1829–37. https://doi.org/10.1161/CIRCULATIONAHA.106.649426 .
doi: 10.1161/CIRCULATIONAHA.106.649426
pubmed: 17030678
Vasan RS, Sullivan LM, D’Agostino RB, et al. Serum insulin-like growth factor I and risk for heart failure in elderly individuals without a previous myocardial infarction: the Framingham Heart Study. Ann Intern Med. 2003;139:642. https://doi.org/10.7326/0003-4819-139-8-200310210-00007 .
doi: 10.7326/0003-4819-139-8-200310210-00007
pubmed: 14568852
Felger JC. Role of inflammation in depression and treatment implications. In: Macaluso M, Preskorn SH, editors. Antidepressants. Cham: Springer International Publishing; 2018. p. 255–86.
doi: 10.1007/164_2018_166
Howren MB, Lamkin DM, Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosomat Med. 2009;71:171–86. https://doi.org/10.1097/PSY.0b013e3181907c1b .
doi: 10.1097/PSY.0b013e3181907c1b
Miller AH, Haroon E, Felger JC. Therapeutic implications of brain–immune interactions: treatment in translation. Neuropsychopharmacology. 2017;42:334–59. https://doi.org/10.1038/npp.2016.167 .
doi: 10.1038/npp.2016.167
pubmed: 27555382
Escobar-Morreale HF, Luque-Ramírez M, González F. Circulating inflammatory markers in polycystic ovary syndrome: a systematic review and metaanalysis. Fertil Steril. 2011;95:1048-1058.e2. https://doi.org/10.1016/j.fertnstert.2010.11.036 .
doi: 10.1016/j.fertnstert.2010.11.036
pubmed: 21168133
Escobar-Morreale HF, Calvo RM, Villuendas G, et al. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res. 2003;11:987–96. https://doi.org/10.1038/oby.2003.136 .
doi: 10.1038/oby.2003.136
pubmed: 12917504
Peral B, San Millán JL, Castello R, et al. The methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab. 2002;87:3977–83. https://doi.org/10.1210/jcem.87.8.8715 .
doi: 10.1210/jcem.87.8.8715
pubmed: 12161545
Villuendas G, San Millán JL, Sancho J, Escobar-Morreale HF. The −597 G→A and −174 G→C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab. 2002;87:1134–41. https://doi.org/10.1210/jcem.87.3.8309 .
doi: 10.1210/jcem.87.3.8309
pubmed: 11889177
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women
doi: 10.1210/jcem.84.1.5393
pubmed: 9920077
Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003;24:302–12. https://doi.org/10.1210/er.2003-0004 .
doi: 10.1210/er.2003-0004
pubmed: 12788801
Vgontzas AN, Bixler EO, Chrousos GP. Metabolic disturbances in obesity versus sleep apnoea: the importance of visceral obesity and insulin resistance. J Intern Med. 2003;254:32–44. https://doi.org/10.1046/j.1365-2796.2003.01177.x .
doi: 10.1046/j.1365-2796.2003.01177.x
pubmed: 12823641
Hotamisligil GS, Budavari A, Murray D, Spiegelman BM. Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes. Central role of tumor necrosis factor-alpha. J Clin Invest. 1994;94:1543–9. https://doi.org/10.1172/JCI117495 .
doi: 10.1172/JCI117495
pubmed: 7523453
pmcid: 295304
Chen L, Chen R, Wang H, Liang F. Mechanisms linking inflammation to insulin resistance. Int J Endocrinol. 2015;2015:1–9. https://doi.org/10.1155/2015/508409 .
doi: 10.1155/2015/508409
Halawa B, Salomon P, Jołda-Mydłowska B, Zyśko D. Levels of tumor necrosis factor (TNF-alpha) and interleukin 6 (IL-6) in serum of patients with acute myocardial infarction. Pol Arch Med Wewn. 1999;101:197–203.
pubmed: 10697395
Gao L, Gu Y, Yin X. High Serum tumor necrosis factor-alpha levels in women with polycystic ovary syndrome: a meta-analysis. PLoS ONE. 2016;11: e0164021. https://doi.org/10.1371/journal.pone.0164021 .
doi: 10.1371/journal.pone.0164021
pubmed: 27764100
pmcid: 5072730
Araya AV, Aguirre A, Romero C, et al. Evaluation of tumor necrosis factor alpha production in ex vivo short term cultured whole blood from women with polycystic ovary syndrome. Eur Cytokine Netw. 2002;13:419–24.
pubmed: 12517726
Choi YS, Yang HI, Cho S, et al. Serum asymmetric dimethylarginine, apelin, and tumor necrosis factor-α levels in non-obese women with polycystic ovary syndrome. Steroids. 2012;77:1352–8. https://doi.org/10.1016/j.steroids.2012.08.005 .
doi: 10.1016/j.steroids.2012.08.005
pubmed: 22944040
Sayin NC, Gücer F, Balkanli-Kaplan P, et al. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries or the polycystic ovary syndrome. J Reprod Med. 2003;48:165–70.
pubmed: 12698773
Tarkun I, Cetinarslan B, Türemen E, et al. Association between circulating tumor necrosis factor-alpha, interleukin-6, and insulin resistance in normal-weight women with polycystic ovary syndrome. Metab Syndr Relat Disord. 2006;4:122–8. https://doi.org/10.1089/met.2006.4.122 .
doi: 10.1089/met.2006.4.122
pubmed: 18370758
Thathapudi S, Kodati V, Erukkambattu J, et al. Tumor necrosis factor-alpha and polycystic ovarian syndrome: a clinical, biochemical, and molecular genetic study. Genet Test Mol Biomarkers. 2014;18:605–9. https://doi.org/10.1089/gtmb.2014.0151 .
doi: 10.1089/gtmb.2014.0151
pubmed: 25083576
pmcid: 4150372
Victor VM, Rocha M, Bañuls C, et al. Induction of oxidative stress and human leukocyte/endothelial cell interactions in polycystic ovary syndrome patients with insulin resistance. J Clin Endocrinol Metab. 2011;96:3115–22. https://doi.org/10.1210/jc.2011-0651 .
doi: 10.1210/jc.2011-0651
pubmed: 21778215
Xiong Y, Liang X, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;159:148–50. https://doi.org/10.1016/j.ejogrb.2011.07.012 .
doi: 10.1016/j.ejogrb.2011.07.012
pubmed: 21908093
Jakubowska J, Bohdanowicz-Pawlak A, Milewicz A, et al. Plasma cytokines in obese women with polycystic ovary syndrome, before and after metformin treatment. Gynecol Endocrinol. 2008;24:378–84. https://doi.org/10.1080/09513590802128968 .
doi: 10.1080/09513590802128968
pubmed: 18645710
Hotamisligil GS, Arner P, Caro JF, et al. Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance. J Clin Invest. 1995;95:2409–15. https://doi.org/10.1172/JCI117936 .
doi: 10.1172/JCI117936
pubmed: 7738205
pmcid: 295872
Hotamisligil GS, Spiegelman BM. Tumor necrosis factor alpha: a key component of the obesity-diabetes link. Diabetes. 1994;43:1271–8. https://doi.org/10.2337/diab.43.11.1271 .
doi: 10.2337/diab.43.11.1271
pubmed: 7926300
Roytblat L, Rachinsky M, Fisher A, et al. Raised interleukin-6 levels in obese patients. Obes Res. 2000;8:673–5. https://doi.org/10.1038/oby.2000.86 .
doi: 10.1038/oby.2000.86
pubmed: 11225716
Straczkowski M, Dzienis-Straczkowska S, Stêpieñ A, et al. Plasma interleukin-8 concentrations are increased in obese subjects and related to fat mass and tumor necrosis factor-alpha system. J Clin Endocrinol Metab. 2002;87:4602–6. https://doi.org/10.1210/jc.2002-020135 .
doi: 10.1210/jc.2002-020135
pubmed: 12364441
Visser M, Bouter LM, McQuillan GM, et al. Elevated C-reactive protein levels in overweight and obese adults. JAMA. 1999;282:2131–5. https://doi.org/10.1001/jama.282.22.2131 .
doi: 10.1001/jama.282.22.2131
pubmed: 10591334
Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica (Cairo). 2016;2016:4071735. https://doi.org/10.1155/2016/4071735 .
doi: 10.1155/2016/4071735
Rasquin Leon LI, Mayrin JV, Polycystic ovarian disease (Stein-Leventhal syndrome). In: StatPearls. StatPearls Publishing: Treasure Island; 2020.
Romitti M, Fabris VC, Ziegelmann PK, et al. Association between PCOS and autoimmune thyroid disease: a systematic review and meta-analysis. Endocr Connect. 2018;7:1158–67. https://doi.org/10.1530/EC-18-0309 .
doi: 10.1530/EC-18-0309
pubmed: 30352422
pmcid: 6215798
Shelton RC, Miller AH. Inflammation in depression: is adiposity a cause? Dialogues Clin Neurosci. 2011;13:41–53.
doi: 10.31887/DCNS.2011.13.1/rshelton
pubmed: 21485745
Xiong Y, Liang X, Yang X, et al. Low-grade chronic inflammation in the peripheral blood and ovaries of women with polycystic ovarian syndrome. Eur J Obstet Gynecol Reprod Biol. 2011;159:148–50. https://doi.org/10.1016/j.ejogrb.2011.07.012 .
doi: 10.1016/j.ejogrb.2011.07.012
pubmed: 21908093
Mobeen H, Afzal N, Kashif M. Polycystic ovary syndrome may be an autoimmune disorder. Scientifica. 2016;2016:1–7. https://doi.org/10.1155/2016/4071735 .
doi: 10.1155/2016/4071735
Haapakoski R, Ebmeier KP, Alenius H, Kivimäki M. Innate and adaptive immunity in the development of depression: an update on current knowledge and technological advances. Prog Neuropsychopharmacol Biol Psychiatry. 2016;66:63–72. https://doi.org/10.1016/j.pnpbp.2015.11.012 .
doi: 10.1016/j.pnpbp.2015.11.012
pubmed: 26631274
pmcid: 4736094
Quan N, Banks WA. Brain-immune communication pathways. Brain Behav Immun. 2007;21:727–35. https://doi.org/10.1016/j.bbi.2007.05.005 .
doi: 10.1016/j.bbi.2007.05.005
pubmed: 17604598
Blakely RD, Berson HE. Molecular biology of serotonin receptors and transporters. Clin Neuropharmacol. 1992;15:351A-352A. https://doi.org/10.1097/00002826-199201001-00182 .
doi: 10.1097/00002826-199201001-00182
pubmed: 1498868
Zhu C-B, Carneiro AM, Dostmann WR, et al. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem. 2005;280:15649–58. https://doi.org/10.1074/jbc.M410858200 .
doi: 10.1074/jbc.M410858200
pubmed: 15728187
Zhu C-B, Lindler KM, Owens AW, et al. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology. 2010;35:2510–20. https://doi.org/10.1038/npp.2010.116 .
doi: 10.1038/npp.2010.116
pubmed: 20827273
pmcid: 3055584
Hardy OT, Czech MP, Corvera S. What causes the insulin resistance underlying obesity? Curr Opin Endocrinol Diabetes Obes. 2012;19:81–7. https://doi.org/10.1097/MED.0b013e3283514e13 .
doi: 10.1097/MED.0b013e3283514e13
pubmed: 22327367
pmcid: 4038351
Miller GE, Freedland KE, Carney RM, et al. Pathways linking depression, adiposity, and inflammatory markers in healthy young adults. Brain Behav Immun. 2003;17:276–85. https://doi.org/10.1016/S0889-1591(03)00057-6 .
doi: 10.1016/S0889-1591(03)00057-6
pubmed: 12831830
Moran LJ, Pasquali R, Teede HJ, et al. Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. Fertil Steril. 2009;92:1966–82. https://doi.org/10.1016/j.fertnstert.2008.09.018 .
doi: 10.1016/j.fertnstert.2008.09.018
pubmed: 19062007
Akbaraly TN, Kivimaki M, Brunner EJ, et al. Association between metabolic syndrome and depressive symptoms in middle-aged adults: results from the Whitehall II study. Diabetes Care. 2009;32:499–504. https://doi.org/10.2337/dc08-1358 .
doi: 10.2337/dc08-1358
pubmed: 19106378
pmcid: 2646036
Gil K, Radziłłowicz P, Zdrojewski T, et al. Relationship between the prevalence of depressive symptoms and metabolic syndrome. Results of the SOPKARD Project. Kardiol Pol. 2006;64:464–9.
pubmed: 16752328
Heiskanen TH, Niskanen LK, Hintikka JJ, et al. Metabolic syndrome and depression: a cross-sectional analysis. J Clin Psychiatry. 2006;67:1422–7. https://doi.org/10.4088/JCP.v67n0913 .
doi: 10.4088/JCP.v67n0913
pubmed: 17017829
Kinder LS, Carnethon MR, Palaniappan LP, et al. Depression and the metabolic syndrome in young adults: findings from the Third National Health and Nutrition Examination Survey. Psychosom Med. 2004;66:316–22. https://doi.org/10.1097/01.psy.0000124755.91880.f4 .
doi: 10.1097/01.psy.0000124755.91880.f4
pubmed: 15184689
Raikkonen K, Matthews KA, Kuller LH. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions. Diabetes Care. 2007;30:872–7. https://doi.org/10.2337/dc06-1857 .
doi: 10.2337/dc06-1857
pubmed: 17392548
Räikkönen K, Matthews KA, Kuller LH. The relationship between psychological risk attributes and the metabolic syndrome in healthy women: antecedent or consequence? Metab Clin Exp. 2002;51:1573–7. https://doi.org/10.1053/meta.2002.36301 .
doi: 10.1053/meta.2002.36301
pubmed: 12489070